Citi assumes Acceleron at Buy, sees ‘significant’ upside potential. Citi analyst Yigal Nochomovitz assumed coverage of Acceleron Pharma with a Buy rating and boosted his price target for the shares to $66 from $63. The analyst sees potential for “significant” share upside over the next 12-18 months with lead drug Luspatercept launching in early 2020, catalysts from Luspatercept expansion and an evolving pipeline.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.